文献速递哮喘

解锁哮喘缓解:专家圆桌讨论的关键见解

Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion.
PubMed 文献 · Respirology · 2025-05-23

本文基于27位哮喘专家的圆桌讨论,探讨重度哮喘治疗目标向以精准医学为导向的缓解范式演变。专家认为接受靶向生物制剂或大环内酯类治疗者中约1/3至1/5可长期维持低疾病活动度,将达成的临床状态标记为临床缓解具有临床、政策和科学价值,但当前缓解率因定义差异而显著不同,需进一步研究以达成可接受定义并纳入患者声音。

要点

  • 重度哮喘治疗目标正转向以精准医学为导向的缓解范式,需多维度长期评估。
  • 接受靶向生物制剂或大环内酯类治疗者中约1/3至1/5可长期维持低疾病活动度。
  • 当前缓解率因定义差异而显著不同,需进一步研究以达成可接受定义。

核心结论

  • 治疗诱导的临床缓解概念在哮喘中是可能且有价值的,但定义仍需进一步完善。

研究设计与样本

  • 与27位哮喘专家进行圆桌讨论,对讨论内容进行叙述性综合与总结。

主要发现

  • 接受靶向生物制剂或大环内酯类治疗者中约1/3至1/5可长期维持低疾病活动度。
  • 专家一致认为将达成的临床状态标记为临床缓解具有临床、政策和科学价值。
  • 当前缓解率因定义差异而显著不同,评估缓解时需考虑混杂因素(如因肾上腺功能不全使用类固醇)。

关键数值与推荐

  • 已提出多种缓解定义,范围从症状控制和无急性发作到潜在病理生物学缓解,各参数严格程度不一。

临床怎么用

  • 临床缓解可作为临床工具(如促进达标治疗)、政策工具(如拓宽生物制剂资格标准)和科学工具(如理解治愈路径)。
  • 评估缓解时需考虑混杂因素(如因肾上腺功能不全使用类固醇)。

局限性

  • 缓解概念仍处于新兴阶段,定义存在变异性,需更多研究以达成可接受定义。
  • 需在研究纳入患者声音。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment targets in severe asthma have evolved towards a remission-focused paradigm guided by precision medicine. This novel concept requires a shift from evaluating the efficacy of therapies based on a single outcome at a single time point to an outcome that captures the complexity of asthma remission involving several domains assessed over a sustained period. Since the concept is still emerging, multiple definitions have been proposed, ranging from symptom control and exacerbation-free to resolution of underlying pathobiology, with varying rigour in each parameter. Understanding the strengths and weaknesses of the current construct is needed to progress further. We conducted a roundtable discussion with 27 asthma experts to address this issue, and discussions were narratively synthesised and summarised. The participants observed that between one in three and one in five people treated with targeted biological therapies or macrolides experience low disease activity over a sustained period. They unanimously agreed that labelling the attained clinical state as clinical remission is useful as a clinical (e.g., facilitating a treat-to-target approach), policy (e.g., widening eligibility criteria for biologics), and scientific (e.g., a path to understanding cure) tool. Current remission rates vary significantly due to definition variability. When assessing remission, it is essential to consider confounding factors (e.g., steroid use for adrenal insufficiency). More research is required to reach an acceptable definition, and including the patient's voice in such research is essential. In conclusion, the concept of treatment-induced clinical remission is possible and valuable in asthma. However, further refinement of the definition is required.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Thomas, Lewthwaite, Gibson, et al. Unlocking Asthma Remission: Key Insights From an Expert Roundtable Discussion. Respirology. 2025. PMID: 40407301. doi:10.1111/resp.70047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。